Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

Name: Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
Published: 2026
License: Public Domain

Shanghai Zhongshan Hospital · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

carcinoma multimodal na neoplasms

carcinoma, hepatocellular, neoplasms, glandular and epithelial, adenocarcinoma, digestive system neoplasms, liver neoplasms, multimodal, tislelizumab, lenvatinib, tace, unresectable primary liver cancer, interventional, na

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

Related documents